Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Journal of Clinical Psychopharmacology
|
May 1, 2012
Open-label treatment with olanzapine for patients with borderline personality disorder
Mary C Zanarini, S Charles Schulz, Holland Detke, et al.
Inflammopharmacology
|
November 27, 2023
Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19
Fangyi Zhao, Kai Zhang, Hongyu Chen, et al.
Inorganic Chemistry
|
December 29, 2025
Synergistic Modulation of Multimodal Luminescence in Self-Activated Phosphors for Advanced Anticounterfeiting and X-ray Imaging
Heyi Yang, Chen Guo, Jiabao Yin, et al.
The Journal of Clinical Psychiatry
|
May 4, 2011
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study
Mary C Zanarini, S Charles Schulz, Holland C Detke, et al.
The Journal of Clinical Psychiatry
|
August 5, 2011
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
Bonnie A Fijal, Virginia L Stauffer, Bruce J Kinon, et al.
Medical Devices (Auckland, N.Z.)
|
October 28, 2016
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
Kristina Callis Duffin, Michael Bukhalo, Margaret A Bobonich, et al.
Frontiers in Psychology
|
March 11, 2020
Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism
Ming Li, Xiaoxiao Yao, Lihua Sun, et al.
BMC Psychiatry
|
September 28, 2011
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
Haya Ascher-Svanum, Fangyi Zhao, Holland C Detke, et al.
Journal of Personalized Medicine
|
February 11, 2016
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
Laura K Nisenbaum, AnnCatherine M Downing, Fangyi Zhao, et al.
The Journal of Clinical Psychiatry
|
September 13, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
John P Houston, Jared Kohler, Jeffrey R Bishop, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Journal of Clinical Psychopharmacology
|
May 1, 2012
Open-label treatment with olanzapine for patients with borderline personality disorder
Mary C Zanarini, S Charles Schulz, Holland Detke, et al.
Inflammopharmacology
|
November 27, 2023
Therapeutic potential and possible mechanisms of ginseng for depression associated with COVID-19
Fangyi Zhao, Kai Zhang, Hongyu Chen, et al.
Inorganic Chemistry
|
December 29, 2025
Synergistic Modulation of Multimodal Luminescence in Self-Activated Phosphors for Advanced Anticounterfeiting and X-ray Imaging
Heyi Yang, Chen Guo, Jiabao Yin, et al.
The Journal of Clinical Psychiatry
|
May 4, 2011
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study
Mary C Zanarini, S Charles Schulz, Holland C Detke, et al.
The Journal of Clinical Psychiatry
|
August 5, 2011
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone
Bonnie A Fijal, Virginia L Stauffer, Bruce J Kinon, et al.
Medical Devices (Auckland, N.Z.)
|
October 28, 2016
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
Kristina Callis Duffin, Michael Bukhalo, Margaret A Bobonich, et al.
Frontiers in Psychology
|
March 11, 2020
Effects of Electroconvulsive Therapy on Depression and Its Potential Mechanism
Ming Li, Xiaoxiao Yao, Lihua Sun, et al.
BMC Psychiatry
|
September 28, 2011
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
Haya Ascher-Svanum, Fangyi Zhao, Holland C Detke, et al.
Journal of Personalized Medicine
|
February 11, 2016
Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
Laura K Nisenbaum, AnnCatherine M Downing, Fangyi Zhao, et al.
The Journal of Clinical Psychiatry
|
September 13, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia
John P Houston, Jared Kohler, Jeffrey R Bishop, et al.
Page
of 5